381 related articles for article (PubMed ID: 2470557)
1. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Digestion; 1989; 42(2):61-9. PubMed ID: 2475379
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
[TBL] [Abstract][Full Text] [Related]
6. CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
Iwamoto Y; Yamamoto R; Kuzuya T
Pancreas; 1987; 2(1):85-90. PubMed ID: 2437574
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
Akiyama T; Otsuki M
Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effect of CR 1409 (cholecystokinin antagonist) on pancreatic exocrine secretion in rats].
Shiratori K; Watanabe S; Shimizu K; Moriyoshi Y; Chang JH; Takeuchi T
Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):70-6. PubMed ID: 2471850
[TBL] [Abstract][Full Text] [Related]
10. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas.
Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S
Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
12. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues.
Niederau C; Niederau M; Williams JA; Grendell JH
Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321
[TBL] [Abstract][Full Text] [Related]
13. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini.
Iwamoto Y; Nakamura R; Akanuma Y
Gastroenterol Jpn; 1984 Feb; 19(1):53-8. PubMed ID: 6202584
[TBL] [Abstract][Full Text] [Related]
15. CCK receptor antagonist loxiglumide alters uptake of CCK in perfused liver and pancreatic acini of the rat.
Beckh K; Göke R; Ruff W; Koop I; Arnold R; Adler G
Digestion; 1991; 48(2):98-103. PubMed ID: 1868975
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion.
Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T
Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844
[TBL] [Abstract][Full Text] [Related]
17. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man.
Gabryelewicz A; Kulesza E; Konturek SJ
Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088
[TBL] [Abstract][Full Text] [Related]
18. Structural features of various proglumide-related cholecystokinin receptor antagonists.
Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD
Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
20. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.
Hildebrand P; Beglinger C; Gyr K; Jansen JB; Rovati LC; Zuercher M; Lamers CB; Setnikar I; Stalder GA
J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
